Karisa Son
Adult Health · Las Vegas, NVNPI 1780064212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 487 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,115, 4.4 times the $705 reported in 2021. Among adult health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 487 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$964
- Regeneron Healthcare Solutions, Inc.$729
- Lilly USA, LLC$599
- Amgen$589
- plus $3K from 19 others
What the payments were for
- Food & beverage$9,11692%
- Education$8118%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 70 | $1,840 |
| AbbVie | 107 | $1,811 |
| Sun Pharmaceutical Industries Inc. | 47 | $964 |
| Regeneron Healthcare Solutions, Inc. | 25 | $729 |
| Lilly USA, LLC | 27 | $599 |
| Amgen | 33 | $589 |
| Galderma Laboratories, L.p. | 19 | $491 |
| LEO Pharma Inc. | 26 | $470 |
| Pfizer | 29 | $443 |
| Novartis | 23 | $393 |
| Sanofi | 20 | $380 |
| UCB, Inc. | 14 | $291 |
| Incyte Corporation | 13 | $262 |
| Arcutis Biotherapeutics, Inc. | 11 | $185 |
| Boehringer Ingelheim | 6 | $177 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $124 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Biofrontera Inc. | 2 | $27 |
| Journey Medical Corporation | 2 | $26 |
| Almirall LLC | 1 | $21 |
| Botanix SB Inc | 1 | $20 |
| Smith+Nephew | 1 | $15 |
| Dermavant Sciences, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Bioventus LLC | 1 | $12 |
How this compares
$9,927 in reported general payments places this provider in the 95th percentile of 90 adult health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 12 | $68,769 |
| OpzeluraRuxolitinib Phosphate | 17 | $32,707 |
| Tacrolimus | 96 | $11,272 |
| Betamethasone Valerate | 137 | $3,469 |
| Ivermectin | 22 | $3,342 |
| Tretinoin | 50 | $3,079 |
| Ammonium Lactate | 157 | $3,077 |
| Fluocinonide | 73 | $2,711 |
| Ketoconazole | 138 | $2,384 |
| Dutasteride | 47 | $2,289 |
| Calcipotriene | 19 | $2,141 |
| Azelaic Acid | 22 | $2,000 |
| Clindamycin Phosphate | 41 | $1,714 |
| Triamcinolone Acetonide | 119 | $1,541 |
| Ciclopirox | 45 | $1,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $589 | $68,76912 claims |
| Incyte CorporationOpzelura | $262 | $32,70717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 adult health providers in Nevada.
Other adult health in Las Vegas
- Marcia Castro-RosenbergLas Vegas$64K
- Amanda SquiersLas Vegas$36K
- Jasmina FornbacherLas Vegas$14K
- Marcella PomeranzLas Vegas$14K
- Jessica LuceroLas Vegas$6K
- Monica LynamLas Vegas$5K
- Thomas McNeilLas Vegas$5K
- Roger ConantLas Vegas$4K
- Ruth RamirezLas Vegas$4K
- Gener CruzLas Vegas$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.